UY29771A1 - Nueva forma cristalina - Google Patents
Nueva forma cristalinaInfo
- Publication number
- UY29771A1 UY29771A1 UY29771A UY29771A UY29771A1 UY 29771 A1 UY29771 A1 UY 29771A1 UY 29771 A UY29771 A UY 29771A UY 29771 A UY29771 A UY 29771A UY 29771 A1 UY29771 A1 UY 29771A1
- Authority
- UY
- Uruguay
- Prior art keywords
- crystal form
- new crystal
- crystalline form
- pyridazino
- acetamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se describe una nueva forma cristalina de 7-cloro-N, N, 5-trimetil-4-oxo-3-fenil-3,5-dihidro-4H-piridazino(4,5-b)indol-1-acetamida, procesos para preparar dicha forma cristalina, composiciones que comprenden dicha forma mezclada con uno o más excipientes farmacéuticamente aceptables, y usos para la misma. El compuesto posee una alta afinidad por receptores de benzodiazepina de tipo periferico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71215305P | 2005-08-29 | 2005-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY29771A1 true UY29771A1 (es) | 2007-03-30 |
Family
ID=37546937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY29771A UY29771A1 (es) | 2005-08-29 | 2006-08-29 | Nueva forma cristalina |
Country Status (32)
Country | Link |
---|---|
US (1) | US7683062B2 (es) |
EP (1) | EP1924585B1 (es) |
JP (1) | JP5063600B2 (es) |
KR (2) | KR20130087059A (es) |
CN (1) | CN101253176B (es) |
AR (1) | AR057099A1 (es) |
AT (1) | ATE531717T1 (es) |
AU (1) | AU2006285142B2 (es) |
BR (1) | BRPI0615259A2 (es) |
CA (1) | CA2619284C (es) |
CR (1) | CR9723A (es) |
CY (1) | CY1112317T1 (es) |
DK (1) | DK1924585T3 (es) |
EA (1) | EA014164B1 (es) |
EC (1) | ECSP088209A (es) |
ES (1) | ES2375841T3 (es) |
HK (1) | HK1123794A1 (es) |
HR (1) | HRP20120073T1 (es) |
IL (1) | IL189276A (es) |
MA (1) | MA30000B1 (es) |
NO (1) | NO20081365L (es) |
NZ (1) | NZ566087A (es) |
PL (1) | PL1924585T3 (es) |
PT (1) | PT1924585E (es) |
RS (1) | RS52318B (es) |
SI (1) | SI1924585T1 (es) |
TN (1) | TNSN08059A1 (es) |
TW (1) | TW200813060A (es) |
UA (1) | UA91716C2 (es) |
UY (1) | UY29771A1 (es) |
WO (1) | WO2007027525A1 (es) |
ZA (1) | ZA200801890B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004311544A1 (en) * | 2003-11-17 | 2005-07-21 | Merck & Cie | Crystalline forms of (6R) -L-erythro-tetrahydrobiopterin dihydrochloride |
EP1776365B1 (en) * | 2004-06-02 | 2011-08-03 | Sandoz Ag | Meropenem intermediate in crystalline form |
CN101287706A (zh) * | 2005-09-21 | 2008-10-15 | 尼科梅德有限责任公司 | 作为组蛋白脱乙酰基酶抑制剂的磺酰基吡咯盐酸盐 |
JP2009513702A (ja) * | 2005-10-31 | 2009-04-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ピペラジニルおよびジアザパニルベンズアミド誘導体の新規な製造方法 |
PL2044020T3 (pl) * | 2006-06-16 | 2011-09-30 | H Lundbeck As | Krystaliczne postaci 4-[2-(4-metylofenylosulfanylo)-fenylo]piperydyny z równoczesnym hamowaniem wychwytu zwrotnego serotoniny i norepinefryny do leczenia bólu neuropatycznego |
EP2076516B1 (en) * | 2006-10-27 | 2013-12-11 | Signal Pharmaceuticals LLC | Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith |
EP2085397A1 (en) * | 2008-01-21 | 2009-08-05 | Esteve Quimica, S.A. | Crystalline form of abacavir |
US7935817B2 (en) * | 2008-03-31 | 2011-05-03 | Apotex Pharmachem Inc. | Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof |
AR071318A1 (es) * | 2008-04-15 | 2010-06-09 | Basilea Pharmaceutica Ag | Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso |
US8097719B2 (en) * | 2008-07-15 | 2012-01-17 | Genesen Labs | Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem |
CN102186854A (zh) * | 2008-08-18 | 2011-09-14 | 赛诺菲-安万特美国有限责任公司 | 制备7-氯-N,N,5-三甲基-4-氧代-3-苯基-3,5-二氢-4H-哒嗪并[4,5-b]吲哚-1-乙酰胺的多晶型的方法 |
KR101846136B1 (ko) | 2010-03-12 | 2018-04-05 | 오메로스 코포레이션 | Pde10 억제제 및 관련 조성물 및 방법 |
SG188361A1 (en) * | 2010-09-01 | 2013-04-30 | Arena Pharm Inc | Non-hygroscopic salts of 5-ht2c agonists |
WO2013044816A1 (en) * | 2011-09-30 | 2013-04-04 | Sunshine Lake Pharma Co., Ltd. | Crystalline forms of azilsartan and preparation and uses thereof |
NZ716494A (en) | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
NZ630803A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Optically active pde10 inhibitor |
US9879002B2 (en) | 2015-04-24 | 2018-01-30 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
US9920045B2 (en) | 2015-11-04 | 2018-03-20 | Omeros Corporation | Solid state forms of a PDE10 inhibitor |
CN111303230B (zh) * | 2020-03-09 | 2021-07-13 | 中国食品药品检定研究院 | 一种黄体酮共晶物及其制备方法和用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2766823B1 (fr) | 1997-07-30 | 1999-10-08 | Synthelabo | Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique |
FR2788696B1 (fr) * | 1999-01-26 | 2004-03-05 | Synthelabo | Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central |
FR2829939B3 (fr) | 2001-09-21 | 2003-11-28 | Sanofi Synthelabo | Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide |
US20050220881A1 (en) | 2003-10-10 | 2005-10-06 | Bvm Holding Co. | Pharmaceutical composition |
-
2006
- 2006-08-24 ZA ZA200801890A patent/ZA200801890B/xx unknown
- 2006-08-24 AU AU2006285142A patent/AU2006285142B2/en not_active Ceased
- 2006-08-24 JP JP2008529130A patent/JP5063600B2/ja not_active Expired - Fee Related
- 2006-08-24 KR KR1020137018636A patent/KR20130087059A/ko not_active Application Discontinuation
- 2006-08-24 UA UAA200803953A patent/UA91716C2/ru unknown
- 2006-08-24 NZ NZ566087A patent/NZ566087A/en not_active IP Right Cessation
- 2006-08-24 WO PCT/US2006/033254 patent/WO2007027525A1/en active Application Filing
- 2006-08-24 AT AT06813757T patent/ATE531717T1/de active
- 2006-08-24 CN CN2006800314750A patent/CN101253176B/zh not_active Expired - Fee Related
- 2006-08-24 ES ES06813757T patent/ES2375841T3/es active Active
- 2006-08-24 SI SI200631252T patent/SI1924585T1/sl unknown
- 2006-08-24 RS RS20120032A patent/RS52318B/en unknown
- 2006-08-24 PL PL06813757T patent/PL1924585T3/pl unknown
- 2006-08-24 EP EP06813757A patent/EP1924585B1/en active Active
- 2006-08-24 PT PT06813757T patent/PT1924585E/pt unknown
- 2006-08-24 EA EA200800716A patent/EA014164B1/ru not_active IP Right Cessation
- 2006-08-24 KR KR1020087004953A patent/KR20080050577A/ko active IP Right Grant
- 2006-08-24 BR BRPI0615259-7A patent/BRPI0615259A2/pt not_active IP Right Cessation
- 2006-08-24 CA CA2619284A patent/CA2619284C/en not_active Expired - Fee Related
- 2006-08-24 DK DK06813757.9T patent/DK1924585T3/da active
- 2006-08-28 AR ARP060103740A patent/AR057099A1/es not_active Application Discontinuation
- 2006-08-29 TW TW095131681A patent/TW200813060A/zh unknown
- 2006-08-29 UY UY29771A patent/UY29771A1/es unknown
-
2008
- 2008-02-04 IL IL189276A patent/IL189276A/en not_active IP Right Cessation
- 2008-02-06 TN TNP2008000059A patent/TNSN08059A1/en unknown
- 2008-02-11 CR CR9723A patent/CR9723A/es unknown
- 2008-02-14 US US12/031,243 patent/US7683062B2/en not_active Expired - Fee Related
- 2008-02-20 EC EC2008008209A patent/ECSP088209A/es unknown
- 2008-03-14 NO NO20081365A patent/NO20081365L/no not_active Application Discontinuation
- 2008-03-17 MA MA30757A patent/MA30000B1/fr unknown
-
2009
- 2009-02-19 HK HK09101601.0A patent/HK1123794A1/xx not_active IP Right Cessation
-
2012
- 2012-01-23 HR HRP20120073TT patent/HRP20120073T1/hr unknown
- 2012-01-26 CY CY20121100092T patent/CY1112317T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY29771A1 (es) | Nueva forma cristalina | |
CL2008001951A1 (es) | Compuestos derivados de imidazo[1,2-a]pirimidin-2-ilmetil sustituidos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el trastorno del sueno, depresion, ansiedad, trastorno relacionado con el abuso de sustancias, entre otras. | |
ECSP077316A (es) | Compuestos imidazo-3-il-amina bicíclicos sustituidos | |
CL2007002167A1 (es) | Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer. | |
CL2007001613A1 (es) | Compuesto de particulas colorantes y/o de carga organica, recubiertas parcialmente con una composicion que contiene particulas de dolomita y ligante; procedimiento para preparar el compuesto, suspension acuosa; uso del compuesto; ayuvante de filtraci | |
CL2007003686A1 (es) | Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral. | |
CL2008001821A1 (es) | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. | |
ATE509634T1 (de) | Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel | |
CL2008002538A1 (es) | Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral | |
CL2007001995A1 (es) | Compuestos derivados de pirrolotriazina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el cancer. | |
CL2009000512A1 (es) | Compuestos heterociclicos sustituidos derivados de imidazo[4,5-d]piridazina, imidazo[4,5-c]piridazina, imidazo[4,5d]pirimidina, entre otros; composicion farmaceutica que comprende a dichos comppuestos; y uso para tratar el virus de la hepatitis c. | |
CL2008002049A1 (es) | Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
CL2008002295A1 (es) | Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
AR049274A1 (es) | Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2 | |
CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
AR058308A1 (es) | Fragmentos vip y metodos de uso de los mismos | |
PA8577201A1 (es) | 3-fenil-propionamido, 3-fenil-acrilamido y derivados 3-fenil-propinamido como inhibidores de mao-b | |
BRPI0513944A (pt) | forma substancialmente pura de um composto de quinazolina, uso de um composto de quinazolina e composição | |
CL2012001596A1 (es) | Compuestos derivados de triazolopiridina, pirazolopirimidina, triazolopirimidina o pirazolopiridina, modulador alosterico positivo del receptor mglur5; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la esquizofrenia o de una enfermedad cognitiva. | |
UY27727A1 (es) | Nueva composicion farmacéutica- | |
GT200600106A (es) | Agentes endoparasiticidas | |
SV2006002089A (es) | Nuevos imidazoles ref. docket 18699 (pc26195a) | |
AR086573A2 (es) | Derivados de 5-(piridin-3-il)-1-azabiciclo[3,2,1]octano y octeno, su preparacion y su aplicacion en terapeutica | |
CL2014000606A1 (es) | Combinacion farmaceutica que comprende al compuesto 2-{2-[(2s)-2-metil-2,3-dihidro-1h-indol-1-il]-2-oxoetil}-6-(morfolin-4-il)pirimidin-4-(3h)-ona y al menos un inhibidor de la via de mapk; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento del cancer. |